OncoOne

OncoOne is a biotechnology company developing new cancer treatments using targeted radiopharmaceuticals. Through its proprietary PreTarg-it® technology, OncoOne enables the pretargeted delivery of radionuclides to tumors via antibody-based targeting approaches, achieving high tumor-to-non-tumor ratios and expanded therapeutic windows.

The company combines expertise in antibody engineering, target biology, and translational oncology to advance precision radioimmunotherapy programs from discovery through clinical development. Founded in 2018, OncoOne has built a strong scientific and operational infrastructure, supported by strategic partnerships with leading CROs and CDMOs and guided by an experienced leadership team with a proven track record in drug development.